rizatriptan and Acute Disease studies

Research Excerpts

Excerpt	Relevance	Reference
"Rizatriptan 10-mg ODT was superior to placebo at all pain end points for treatment of acute migraine in patients using topiramate for migraine prophylaxis."	2.77	Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis. ( Cady, RK; Connor, KM; Ge, Y; Ho, TW; Hustad, CM; MacGregor, A; Schaefer, E; Seeburger, JL; Strickler, N; Valade, D; Winner, P; Zhang, Y, 2012)
"Frovatriptan was as effective as rizatriptan in the immediate treatment of menstrually related migraine attacks while showing a favorable sustained effect with a lower rate of migraine recurrence."	2.76	Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. ( Ferrari, MD; Lisotto, C; Omboni, S; Pinessi, L; Savi, L; Zanchin, G; Zava, D, 2011)
"Eligible patients with migraine according to International Headache Society criteria treated a single migraine attack of moderate or severe intensity within 4 h from pain onset."	2.73	Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. ( Diamond, M; Diamond, S; Freitag, F; Janssen, I; Rodgers, A; Skobieranda, F, 2008)
"Adult women with ICHD-II menstrual migraine were assigned to either rizatriptan 10-mg tablet or placebo in a 2 : 1 ratio."	2.73	Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. ( Hustad, CM; Loder, E; Mannix, LK; Mueller, L; Nett, R; Ramsey, KE; Rodgers, A; Skobieranda, F, 2007)
"One hundred and fifty-five migraine patients were randomised to rizatriptan 10 mg (53), ibuprofen 400 mg (52) and placebo (50)."	2.73	Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. ( Kalita, J; Misra, UK; Yadav, RK, 2007)
"TAME (Treat A Migraine Early)1 was conducted at 46 centers in the United States; TAME2, at 48 centers in the United States."	2.72	Efficacy of Rizatriptan 10 mg administered early in a migraine attack. ( Cady, R; Hustad, CM; Martin, V; Mauskop, A; Ramsey, KE; Rodgers, A; Skobieranda, F, 2006)
"Gastroparesis frequently happens during migraine attacks, postponing the onset of action of orally administered drugs."	2.72	Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. ( Bigal, ME; Filho, PF; Krymchantowski, AV, 2006)
"Adult migraineurs treated two migraine attacks with either rizatriptan 10-mg standard tablets or rizatriptan 10-mg orally disintegrating tablets in a crossover manner."	2.71	Real-world experiences in migraine therapy with rizatriptan. ( Cutrer, FM; Dayno, J; Goldstein, J; Hu, XH; Jamieson, D, 2003)
"Patients with IHS migraine were randomized to one out of 3 groups, where they had to treat 6 consecutive moderate or severe attacks in counterbalanced order."	2.71	Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. ( Bigal, ME; Krymchantowski, AV, 2004)
"Rizatriptan 5 mg was well tolerated in both the studies, with an adverse event profile not significantly different from that of placebo or standard care."	2.71	Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. ( Cady, R; Klipfel, M; Lewis, D; McCarroll, K; Nett, R; Peng, Y; Strohmaier, K; Visser, WH; Winner, P, 2004)
"Rizatriptan was significantly more effective than non-triptans in the relief of migraine headaches for patients obtaining prescribed migraine medications from a retail pharmacy."	2.71	Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study. ( Adelman, J; Cady, R; Diamond, M; Hu, XH; Martin, V; Sajjan, S, 2004)
" On experiencing moderate or severe migraine headaches, patients rated headache severity prior to dosing and at 30-minute intervals for 2 hours after dosing."	2.69	Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. ( Block, G; Cutler, N; Gross, M; Jiang, K; Reines, S; Smith, B; Teall, J; Tuchman, M; Willoughby, E, 1998)
"Rizatriptan wafer is a 5HT1B/1D agonist for use in the acute treatment of migraine."	2.69	Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine. ( Klapper, JA; O'Connor, S, 2000)
"Rizatriptan (MK-462) is a potent 5HTID receptor agonist."	2.68	Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. ( Block, G; Ferrari, MD; Gijsman, H; Kramer, MS; Matzura-Wolfe, D; Polis, A; Sargent, J; Teall, J; Tuchman, M, 1997)
"Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy."	2.48	Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. ( Derry, CJ; Derry, S; Moore, RA, 2012)
"Rizatriptan is a second-generation triptan marketed as 5 and 10 mg tablets and rapidly disintegrating wafer formulations."	2.42	A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine. ( Pascual, J, 2004)
"Rizatriptan is a new, selective 5-HT1B/1D receptor agonist that is effective for treatment of migraine."	2.41	The use of rizatriptan in the treatment of acute, multiple migraine attacks. ( Saper, JR, 2000)
"There exist increasing options for migraine treatment that may further improve the clinical effects of the older and newer triptans through early treatment of migraine at the stages of mild migraine pain, or even during the prodromal phase of the attack."	2.41	Acute treatment of migraine and the role of triptans. ( Freitag, FG, 2001)
"Thus sumatriptan has become the de facto gold standard and will be thus employed here."	2.40	The scientific basis of medication choice in symptomatic migraine treatment. ( Goadsby, PJ, 1999)
"Significantly, more patients taking rizatriptan achieved both PR and PF within 2 h after dosing than other oral triptans."	1.34	Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. ( Chen, Y; Hu, XH; Ma, L; Ng-Mak, DS; Solomon, G, 2007)
"Migraine is a common disorder that costs US employers billions of dollars each year in missed workdays and reduced productivity."	1.32	Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. ( Reeder, CE; Williams, P, 2003)
"In the treatment of acute migraine, patients need a drug that provides convenient dosing and consistent effectiveness."	1.31	Rizatriptan. Convenience and consistency. ( Evans, RW, 2000)

Research

Studies (36)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (11.11)	18.2507
2000's	28 (77.78)	29.6817
2010's	4 (11.11)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Filla, SA	1
Winter, MA	1
Johnson, KW	1
Bleakman, D	1
Bell, MG	1
Bleisch, TJ	1
Castaño, AM	1
Clemens-Smith, A	1
del Prado, M	1
Dieckman, DK	1
Dominguez, E	1
Escribano, A	1
Ho, KH	1
Hudziak, KJ	1
Katofiasc, MA	1
Martinez-Perez, JA	1
Mateo, A	1
Mathes, BM	1
Mattiuz, EL	1
Ogden, AM	1
Phebus, LA	1
Stack, DR	1
Stratford, RE	1
Ornstein, PL	1
Cui, XP	1
Ye, JX	1
Lin, H	1
Mu, JS	1
Lin, M	1
Freitag, F	1
Diamond, M	2
Diamond, S	1
Janssen, I	1
Rodgers, A	3
Skobieranda, F	3
Evans, RW	1
Cady, RK	2
Vause, CV	1
Ho, TW	2
Bigal, ME	3
Durham, PL	1
Savi, L	1
Omboni, S	1
Lisotto, C	1
Zanchin, G	1
Ferrari, MD	3
Zava, D	1
Pinessi, L	1
Seeburger, JL	1
Winner, P	2
MacGregor, A	1
Valade, D	1
Ge, Y	1
Zhang, Y	1
Hustad, CM	3
Strickler, N	1
Schaefer, E	1
Connor, KM	1
Derry, CJ	1
Derry, S	1
Moore, RA	2
Maizels, M	1
Jamieson, D	1
Cutrer, FM	1
Goldstein, J	1
Dayno, J	1
Hu, XH	3
Major, PW	1
Grubisa, HS	1
Thie, NM	1
Williams, P	1
Reeder, CE	1
Pascual, J	1
Krymchantowski, AV	2
Visser, WH	1
Strohmaier, K	1
Klipfel, M	1
Peng, Y	1
McCarroll, K	1
Cady, R	3
Lewis, D	1
Nett, R	2
Martin, V	2
Adelman, J	1
Sajjan, S	1
Morillo, LE	1
Mauskop, A	1
Ramsey, KE	2
Tfelt-Hansen, P	1
Iversen, HK	1
Filho, PF	1
Mannix, LK	1
Loder, E	1
Mueller, L	1
Ng-Mak, DS	1
Chen, Y	1
Ma, L	1
Solomon, G	1
Misra, UK	1
Kalita, J	1
Yadav, RK	1
Gijsman, H	1
Kramer, MS	1
Sargent, J	1
Tuchman, M	2
Matzura-Wolfe, D	1
Polis, A	1
Teall, J	2
Block, G	2
Cutler, N	1
Gross, M	1
Willoughby, E	1
Smith, B	1
Jiang, K	1
Reines, S	1
Deleu, D	2
Hanssens, Y	2
Goadsby, PJ	3
Scholz, M	1
Klapper, JA	1
O'Connor, S	1
Saper, JR	1
Oldman, AD	1
Smith, LA	1
McQuay, HJ	1
Roon, KI	1
Lipton, RB	1
Freitag, FG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine[NCT00772473]		34 participants (Actual)	Observational	2008-02-29	Completed
Calcitonin Gene-related Peptide (CGRP) Levels in the Pathogenesis of Chronic Migraine[NCT01071096]	Phase 4	20 participants (Actual)	Interventional	2010-06-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis[NCT00812006]	Phase 3	108 participants (Actual)	Interventional	2009-03-24	Completed
A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild[NCT00095004]	Phase 3	167 participants (Actual)	Interventional	2004-10-21	Completed
A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild[NCT00092963]	Phase 3	529 participants (Actual)	Interventional	2004-08-17	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine[NCT00111722]	Phase 3	393 participants (Actual)	Interventional	2005-05-27	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine[NCT00111709]	Phase 3	393 participants (Actual)	Interventional	2005-05-27	Completed
A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence[NCT00897949]	Phase 3	1,473 participants (Actual)	Interventional	1995-03-31	Completed
Effects of Myofascial Trigger Points Therapy in Migraine.[NCT05646160]		100 participants (Anticipated)	Interventional	2018-01-15	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary. (NCT01071096)
Timeframe: Baseline (collected historically at screening) versus (vs.) Month (Mo) 1, Mo 2, Mo 3, Mo 4, Mo 5, Mo 6, and Mo 7

Change in Number of Headache Days Per Month From Baseline to Month 1 (M1), Month 1 to Month 2 (M2), and Month 2 to Month 3 (M3).

Intervention	days (Mean)
	Baseline vs. Month 1	Baseline vs. Month 2	Baseline vs. Month 3	Baseline vs. Month 4	Baseline vs. Month 5	Baseline vs. Month 6	Baseline vs. Month 7
Group A	-7.61	-9.72	-10.06	-9.50	-8.94	-9.50	-6.50
Group B	-6.67	-5.22	-5.22	-6.89	-6.33	-9.22	-4.56

Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary. (NCT01071096)
Timeframe: Baseline (collected historically at screening) vs. Mo 1, Mo 1 vs. Mo 2, Mo 2 vs. Mo 3, Mo 3 vs. Mo 4, Mo 4 vs. Mo 5, Mo 5 vs. Mo 6, and Mo 6 vs. Mo 7

Changes Between Inter-ictal (Baseline) Levels Between Responders and Non-responders

Intervention	days (Mean)
	Baseline vs. Mo 1	Mo 1 vs. Mo 2	Mo 2 vs. Mo 3	Mo 3 vs. Mo 4	Mo 4 vs. Mo 5	Mo 5 vs. Mo 6	Mo 6 vs. M 7
Group A	-7.61	-2.11	-0.33	0.56	0.56	-0.56	3.00
Group B	-6.67	1.44	0.00	-1.67	0.56	-2.89	4.67

Only cytokines with a mean densimetric value 1.65 times the background grey value in a minimum of 3 patients were considered detectable. These are reported below. Values normalized to positive control array spots after background subtraction: C5/C5a, CD40 Ligand, Granulocyte Colony Stimulating Factor (G-CSF), Growth Regulated Oncogene(GRO)-alpha, Soluble Intercellular Adhesion Molecule (sICAM)-1, Interferon gamma (IFN-y), Interleukin(IL)-1alpha, 1beta, 1ra, 8, 16, 17E, & 23, Interferon Gamma-Induced Protein 10 (IP-10), Interferon-inducible T cell alpha chemoattractant (I-TAC), Macrophage Migration Inhibitory Factor (MIF), Serpin E1, and Regulated Upon Activation Normal T-cell Expressed (RANTES) (NCT01071096)
Timeframe: For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3 at Baseline level (inter-ictal) and at onset of headache that is one degree worse than Baseline level and that will be treated with acute therapy

Inter-ictal (Baseline) Levels of Saliva Calcitonin Gene-related Peptide (CGRP)

Intervention	Florescent Units (FU) (Mean)
	C5/C5a	CD40 Ligand	G-CSF	GROa	sICAM-1	IFN-y	IL-1alpha	IL-1beta	IL-1ra	IL-8	IL-16	IL-17E	IL-23	IP-10	I-TAC	MIF	Serpin E1	RANTES
Month 1 vs. Month 3 Non-Responders	3.26	1.22	1.34	0.73	1.51	1.63	0.81	1.03	1.30	2.28	1.10	1.45	2.61	3.11	3.65	1.24	3.16	1.24
Month 1 vs. Month 3 Responders	1.03	0.91	1.07	1.05	3.99	0.91	0.86	1.15	0.88	4.38	0.98	1.28	0.93	1.55	0.67	0.80	0.76	1.14
Month 1 vs. Saline Non-Responders	1.01	1.26	0.93	3.18	0.61	0.80	2.88	1.12	2.02	1.70	2.07	1.02	1.80	0.95	0.28	9.55	0.70	0.77
Month 1 vs. Saline Responders	1.38	1.09	0.92	1.34	2.60	1.29	2.30	1.63	1.13	1.61	0.91	0.86	2.45	1.32	1.40	3.71	0.98	0.95
Month 3 vs. Saline Non-Responders	1.61	1.31	0.99	1.81	2.00	1.92	2.14	0.51	1.90	1.22	1.97	0.42	1.69	2.76	0.94	8.66	0.90	0.91
Month 3 vs. Saline Responders	1.39	0.98	0.85	1.40	5.99	1.29	1.50	1.38	0.96	2.71	0.75	1.59	1.06	0.86	1.01	2.71	0.70	0.93

CGRP Level collected each month when subject did not have a headache or was at lowest pain level of headache that month. (NCT01071096)
Timeframe: Baseline levels collected for OnabotulinumtoxinA and Saline treatment during Months 1 through 7

Saliva CGRP Levels for OnabotulinumtoxinA Responders (Reduction of Headache Days Greater Than 30%) vs. Non-responders and Saline

Intervention	pmol/mg total protein (Mean)
	Treatment Month 1	Treatment Month 2	Treatment Month 3
OnabotulinumtoxinA	39.64	28.37	26.14
Saline	40.79	39.14	50.63

Saliva samples collected at Baseline (at no headache or lowest level of headache), at headache attack directly before taking rescue medication and 2 hours after treating with rescue medication. (NCT01071096)
Timeframe: For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3

Normal Rating of Functional Disability (NRFD)

Intervention	pmol/mg total protein (Mean)
	Treatment Month 1 - Baseline	Treatment Month 1 - Attack	Treatment Month 1 - 2 Hours Post	Treatment Month 2 - Baseline	Treatment Month 2 - Attack	Treatment Month 2 - 2 Hours Post	Treatment Month 3 - Baseline	Treatment Month 3 - Attack	Treatment Month 3 - 2 Hours Post
OnabotulinumtoxinA Non-Responders	29.36	22.36	23.66	28.66	32.65	22.35	32.61	30.17	19.11
OnabotulinumtoxinA Responders	52.36	27.94	61.55	59.89	60.14	39.13	51.33	73.18	54.04
Saline	70.46	36.23	39.76	44.12	33.05	33.93	58.74	46.16	49.39

Level of functional disability was assessed on a paper diary by the participants. Level of functional disability was rated as: normal, mildly impaired, severely impaired, or unable to do activities, requires bedrest. Functional disability ratings was dichotomized to Normal and Not Normal (mildly impaired, severely impaired, or unable to do activities, requires bedrest) for analysis. (NCT00812006)
Timeframe: 2 hours post dose

Pain Freedom (PF)

Intervention	Attacks (Number)
	Resulting in NRFD at 2 hours post dose	Not resulting in NRFD at 2 hours post dose
Placebo	16	77
Rizatriptan	85	108

Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose. (NCT00812006)
Timeframe: 2 hours post dose

Pain Relief (PR)

Intervention	Attacks (Number)
	Resulting in PF 2 hours post dose	Not resulting in PF 2 hours post dose
Placebo	9	84
Rizatriptan	74	119

Pain severity was rated by the participants in a paper diary. Pain severity rating scale : 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose. (NCT00812006)
Timeframe: 2 hours post dose

Sustained Pain Relief (SPR)

Intervention	Attacks (Number)
	Resulting in PR at 2 hours post dose	Not resulting in PR at 2 hours post dose
Placebo	21	72
Rizatriptan	105	88

24-hour sustained pain relief (defined as pain relief at 2 hours post dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the respective period after dosing with the blinded study medication. (NCT00812006)
Timeframe: 2 - 24 hours post dose

Treatment Satisfaction (TS)

Intervention	Attacks (Number)
	Resulting in SPR 2-24 hours post dose	Not resulting in SPR 2-24 hours post dose
Placebo	12	81
Rizatriptan	67	126

Patient satisfaction was assessed on a paper diary by the participants. Level of satisfaction was rated as: completely satisfied, very satisfied, somewhat satisfied, neither satisfied nor dissatisfied, somewhat dissatisfied, very dissatisfied, or completely dissatisfied. The overall 24-hour assessment of study medication was dichotomized to Satisfaction (completely satisfied, very satisfied, somewhat satisfied) and Non-satisfaction (neither satisfied nor dissatisfied, somewhat dissatisfied, very dissatisfied, or completely dissatisfied) for analysis. (NCT00812006)
Timeframe: 24 hours post dose

No Disability at 2 Hours After the Initial Dose of Test Drug

Intervention	Attacks (Number)
	Resulting in TS at 24 hours post dose	Not resulting in TS at 24 hours post dose
Placebo	31	62
Rizatriptan	117	76

Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 - Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Pain Free at 2 Hours After the Initial Dose of Test Drug

Intervention	Participants (Number)
	Normal	Mildly Impaired	Severely Impaired	Requires Bedrest
Placebo	54	118	53	75
Rizatriptan 10 mg	209	148	45	52
Rizatriptan 5 mg	175	160	56	66

Patients reporting pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Pain Relief 2 Hours After Treatment for Headache Recurrence

Intervention	Participants (Number)
	Reporting no pain	Reporting pain
Placebo	30	272
Rizatriptan 10 mg	193	262
Rizatriptan 5 mg	150	307

Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours). (NCT00897949)
Timeframe: 2 hours after treatment for recurrence

Pain Relief at 2 Hours After the Initial Dose of Test Drug

Intervention	Participants (Number)
	Pain relief	No pain relief
Placebo / Rizatriptan 10 mg	18	4
Placebo / Rizatriptan 5 mg	12	5
Rizatriptan 10 mg / Placebo	33	42
Rizatriptan 10 mg / Rizatriptan 10 mg	53	12
Rizatriptan 5 mg / Placebo	32	27
Rizatriptan 5 mg / Rizatriptan 5 mg	39	16

Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Intervention	Participants (Number)
	Reporting pain relief	Not reporting pain relief
Placebo	106	196
Rizatriptan 10 mg	322	133
Rizatriptan 5 mg	285	172

Intervention	Participants (Number)
	Used escape medication	Did not use escape medication
Placebo	128	176
Rizatriptan 10 mg	76	380
Rizatriptan 5 mg	101	357

Article	Year
Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. Pain practice : the official journal of World Institute of Pain, 2015, Volume: 15, Issue:2 Topics: Acute Disease; Azepines; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Imidazoles; M	2015
Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. The Cochrane database of systematic reviews, 2012, Feb-15, Issue:2 Topics: Acute Disease; Administration, Intranasal; Adult; Dihydroergotamine; Female; Humans; Male; Migraine	2012
Triptans for treatment of acute pediatric migraine: a systematic literature review. Pediatric neurology, 2003, Volume: 29, Issue:5 Topics: Acute Disease; Administration, Intranasal; Administration, Oral; Child; Clinical Trials as Topic; Hu	2003
A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:3 Topics: Acute Disease; Administration, Oral; Clinical Trials as Topic; Drug Interactions; Humans; Migraine D	2004
Migraine headache. Clinical evidence, 2003, Issue:10 Topics: Acute Disease; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Dicl	2003
[Triptanes in the treatment of migraine. A review based on three Cochrane reviews]. Ugeskrift for laeger, 2006, May-08, Volume: 168, Issue:19 Topics: Acute Disease; Administration, Oral; Dose-Response Relationship, Drug; Humans; Migraine Disorders; P	2006
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Acta neurologica Belgica, 1999, Volume: 99, Issue:2 Topics: Acute Disease; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Vasospasm; Drug Des	1999
The scientific basis of medication choice in symptomatic migraine treatment. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1999, Volume: 26 Suppl 3 Topics: Acute Disease; Choice Behavior; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorder	1999
Current and emerging second-generation triptans in acute migraine therapy: a comparative review. Journal of clinical pharmacology, 2000, Volume: 40, Issue:7 Topics: Acute Disease; Carbazoles; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidine	2000
Rizatriptan in acute treatment of migraine: update on new comparative data. Cephalalgia : an international journal of headache, 2000, Volume: 20 Suppl 1 Topics: Acute Disease; Clinical Trials as Topic; Humans; Migraine Disorders; Serotonin Receptor Agonists; Tr	2000
The use of rizatriptan in the treatment of acute, multiple migraine attacks. Neurology, 2000, Volume: 55, Issue:9 Suppl 2 Topics: Acute Disease; Humans; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; Triazoles; Trypt	2000
Rizatriptan for acute migraine. The Cochrane database of systematic reviews, 2001, Issue:3 Topics: Acute Disease; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Serotonin Receptor	2001
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (London, England), 2001, Nov-17, Volume: 358, Issue:9294 Topics: Acute Disease; Administration, Oral; Humans; Indoles; Migraine Disorders; Pyrrolidines; Randomized C	2001
Acute treatment of migraine and the role of triptans. Current neurology and neuroscience reports, 2001, Volume: 1, Issue:2 Topics: Acute Disease; Blood Flow Velocity; Carbazoles; Clinical Trials as Topic; Drug Administration Routes	2001

Article	Year
Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache, 2008, Volume: 48, Issue:6 Topics: Acetaminophen; Acute Disease; Adult; Aged; Analgesics, Non-Narcotic; Double-Blind Method; Drug Thera	2008
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache, 2009, Volume: 49, Issue:9 Topics: Acute Disease; Adult; Biomarkers; Calcitonin Gene-Related Peptide; Drug Resistance; Female; Humans;	2009
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache, 2009, Volume: 49, Issue:9 Topics: Acute Disease; Adult; Biomarkers; Calcitonin Gene-Related Peptide; Drug Resistance; Female; Humans;	2009
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache, 2009, Volume: 49, Issue:9 Topics: Acute Disease; Adult; Biomarkers; Calcitonin Gene-Related Peptide; Drug Resistance; Female; Humans;	2009
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache, 2009, Volume: 49, Issue:9 Topics: Acute Disease; Adult; Biomarkers; Calcitonin Gene-Related Peptide; Drug Resistance; Female; Humans;	2009
Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. The journal of headache and pain, 2011, Volume: 12, Issue:6 Topics: Acute Disease; Adolescent; Adult; Aged; Carbazoles; Cross-Over Studies; Double-Blind Method; Female;	2011
Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis. Headache, 2012, Volume: 52, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Disability Evaluation; Double-Blind Method; Female; Fructose	2012
Real-world experiences in migraine therapy with rizatriptan. Headache, 2003, Volume: 43, Issue:3 Topics: Acute Disease; Adult; Female; Follow-Up Studies; Humans; Male; Middle Aged; Migraine Disorders; Pati	2003
Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC neurology, 2004, Jun-28, Volume: 4 Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhi	2004
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache, 2004, Volume: 44, Issue:9 Topics: Acute Disease; Adolescent; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Recurrence	2004
Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study. Headache, 2004, Volume: 44, Issue:9 Topics: Acute Disease; Adolescent; Adult; Analgesics; Female; Humans; Male; Middle Aged; Migraine Disorders;	2004
Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache, 2006, Volume: 46, Issue:6 Topics: Acute Disease; Adult; Female; Humans; Male; Medical Records; Migraine Disorders; Patient Satisfactio	2006
Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache, 2006, Volume: 46, Issue:6 Topics: Acute Disease; Adult; Female; Humans; Male; Medical Records; Migraine Disorders; Patient Satisfactio	2006
Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache, 2006, Volume: 46, Issue:6 Topics: Acute Disease; Adult; Female; Humans; Male; Medical Records; Migraine Disorders; Patient Satisfactio	2006
Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache, 2006, Volume: 46, Issue:6 Topics: Acute Disease; Adult; Female; Humans; Male; Medical Records; Migraine Disorders; Patient Satisfactio	2006
Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia : an international journal of headache, 2006, Volume: 26, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Drug Combinations; Female; Gastrointestinal Agents; Gastropa	2006
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia : an international journal of headache, 2007, Volume: 27, Issue:5 Topics: Acute Disease; Adolescent; Adult; Analgesics; Comorbidity; Double-Blind Method; Female; Humans; Mens	2007
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia : an international journal of headache, 2007, Volume: 27, Issue:5 Topics: Acute Disease; Adolescent; Adult; Analgesics; Comorbidity; Double-Blind Method; Female; Humans; Mens	2007
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia : an international journal of headache, 2007, Volume: 27, Issue:5 Topics: Acute Disease; Adolescent; Adult; Analgesics; Comorbidity; Double-Blind Method; Female; Humans; Mens	2007
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia : an international journal of headache, 2007, Volume: 27, Issue:5 Topics: Acute Disease; Adolescent; Adult; Analgesics; Comorbidity; Double-Blind Method; Female; Humans; Mens	2007
Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. The journal of headache and pain, 2007, Volume: 8, Issue:3 Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Ibuprofen; Male; Migr	2007
Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia : an international journal of headache, 1997, Volume: 17, Issue:6 Topics: Acute Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Logistic Model	1997
Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache, 1998, Volume: 38, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migr	1998
Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine. Cephalalgia : an international journal of headache, 2000, Volume: 20, Issue:6 Topics: Acute Disease; Administration, Oral; Administration, Sublingual; Analgesics; Double-Blind Method; Fl	2000

Article	Year
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. Journal of medicinal chemistry, 2002, Sep-26, Volume: 45, Issue:20 Topics: Acute Disease; Administration, Oral; Animals; Biological Availability; Calcium; Carboxylic Acids; Ce	2002
Rizatriptan. Convenience and consistency. Postgraduate medicine, 2000, Volume: 108, Issue:3 Suppl Topics: Acute Disease; Administration, Oral; Humans; Migraine Disorders; Serotonin Receptor Agonists; Tablet	2000
Rizatriptan 5mg is not efficacious for migraine in adolescents. Headache, 2002, Volume: 42, Issue:8 Topics: Acute Disease; Adolescent; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Seroto	2002
[New onset headache. Which patients should be sent for CT imaging?]. MMW Fortschritte der Medizin, 2002, Oct-24, Volume: 144, Issue:43 Topics: Acute Disease; Brain Diseases; Diagnosis, Differential; Drug Administration Schedule; Headache; Huma	2002
Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Clinical therapeutics, 2003, Volume: 25, Issue:11 Topics: Acute Disease; Cost-Benefit Analysis; Decision Support Techniques; Female; Health Care Costs; Health	2003
Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. International journal of clinical practice, 2007, Volume: 61, Issue:7 Topics: Acute Disease; Adult; Cross-Over Studies; Female; Humans; Male; Middle Aged; Migraine Disorders; Mul	2007
Treatment options for acute migraine. RN, 2000, Volume: 63, Issue:10 Topics: Acute Disease; Adult; Female; Humans; Migraine Disorders; Oxazolidinones; Patient Selection; Practic	2000

rizatriptan and Acute Disease